|
|
 |
The goal of Dr. Liu’s research is to study the regulatory mechanisms of cytokine production from lung cells induced by mechanical ventilation or endotoxin (LPS). His research can be split into two main areas:
i. role of the cytoskeleton in the mechanotransduction of cytokine production; and
ii. to investigate the role of the cytoskeleton in intracellular transport of cytokine for secretion from lung alveolar epithelial cells.
Dr. Liu’s other interests include:
i. The cellular and molecular mechanisms of acute lung injury. Dr. Liu and his team are studying the ischemia-reperfusion induced lung injury in lung transplantation, and other pathogenic factors that induce acute lung injury. They are developing a nano-particular based drug delivery system to prevent and treat lung injury.
ii. Lung repair and regeneration. Dr. Liu and his team are exploring the role of PI3K/Akt pathway in lung tissue injury and repair using transgenic mice with deficiency of an adaptor protein, XB130.
iii. The role of XB130 in tumorigenesis. Dr. Liu and his team demonstrated that XB130 can couple RET/PTC oncogenic kinase to the PI3K pathway in thyroid cancer and also found its role in cancer cells, both in vitro and in vivo.
Dr. Liu’s additional studies are to examine the clinical impact of cytokines in acute lung injury, and to explore cytokine-related molecular therapy.
|
|
Researcher Information
Professor of Surgery, Medicine and Physiology University of Toronto,Director of International Research Relations, Faculty of Medicine,Full Member, Institute of Medical Science, School of Graduate Studies,Director, Center for Research Training and Edu
Medicine and Physiology
Website
2-814-101 College Street
Toronto, Ontario
Canada M5G 1L7
|
|
|
Dr. Liu has lectured throughout the world and published prolifically – he is an internationally recognized leader in the field of cellular and molecular biology. He has received numerous awards, including the Medical Research Council (MRC) Fellowship, MRC Scholarship/Canadian Institute of Health Research (CIHR) New Investigator Award and Premier Research Excellence Award.
Dr. Liu is also the recipient of research grants from CIHR, the Canadian Cystic Fibrosis Foundation and the Canadian Foundation for Innovation.
|
|
Researcher Information
Professor of Surgery, Medicine and Physiology University of Toronto,Director of International Research Relations, Faculty of Medicine,Full Member, Institute of Medical Science, School of Graduate Studies,Director, Center for Research Training and Edu
Medicine and Physiology
Website
2-814-101 College Street
Toronto, Ontario
Canada M5G 1L7
|
|
|
|
Fung SY, Oyaizu T, Yang H, Yuan Y, Han B, Keshavjee S, Liu M.
The potential of nanoscale combinations of self-assembling peptides and amino acids of the Src tyrosine kinase inhibitor in acute lung injury therapy.
Biomaterials. 2011 Jun;32(16):4000-8. Epub 2011 Mar 3.
|
|
|
Shiozaki A, Lodyga M, Bai XH, Nadesalingam J, Oyaizu T, Winer D, Asa SL, Keshavjee S, Liu M.
XB130, a novel adaptor protein, promotes thyroid tumor growth.
Am J Pathol. 2011 Jan;178(1):391-401. Epub 2010 Dec 23.
|
|
|
Mura M, Binnie M, Han B, Li C, Andrade CF, Shiozaki A, Zhang Y, Ferrara N, Hwang D, Waddell TK, Keshavjee S, Liu M.
Functions of type II pneumocyte-derived vascular endothelial growth factor in alveolar structure, acute inflammation, and vascular permeability.
Am J Pathol. 2010 Apr;176(4):1725-34. Epub 2010 Feb 18.
|
|
|
Lodyga M, Bai X, Kapus A, and Liu M.
Adaptor protein XB130 is a Rac-controlled component of lamellipodia that regulates cell motility and invasion.
J Cell Sci. 2010,123,23:4156-69.
|
|
|
Xiao H, Bai XH, Kapus A, Lu WY, Mak AS, and Liu M.
The protein kinase C cascade regulates recruitment of matrix metalloprotease 9 to podosomes and its release and activation.
Mol Cell Biol. 2010,30,23:5545-61.
|
|
|
Researcher Information
Professor of Surgery, Medicine and Physiology University of Toronto,Director of International Research Relations, Faculty of Medicine,Full Member, Institute of Medical Science, School of Graduate Studies,Director, Center for Research Training and Edu
Medicine and Physiology
Website
2-814-101 College Street
Toronto, Ontario
Canada M5G 1L7
|
|
|
|
|
Current screening for lung donor suitability is based on a number of empirical criteria such as donor age, smoking history, arterial blood gas concentrations, chest radiograph findings, bronchoscopic findings and physical examination of the lung at the time of organ retrieval. While these criteria have proven effective, they are imprecise and often lead to rejection of organs that are potentially suitable for transplantation. This has led to lung recovery from only 20% of the available donor pool.
send a message
more
Current screening for lung donor suitability is based on a number of empirical criteria such as donor age, smoking history, arterial blood gas concentrations, chest radiograph findings, bronchoscopic findings and physical examination of the lung at the time of organ retrieval. While these criteria have proven effective, they are imprecise and often lead to rejection of organs that are potentially suitable for transplantation. This has led to lung recovery from only 20% of the available donor pool. The availability of biomarkers that predict outcome after transplantation will greatly assist the clinical assessment of lung donor suitability and potentially improve the efficiency of donor organ utilization and at the same time, improve recipient outcome.
Dr. Keshavjee and colleagues have identified a panel of biomarkers that are differentially expressed in donor lungs. These biomarkers are highly predictive of the risk of primary graft failure in recipients. Using this information, they have developed a new genebased diagnostic tool that will assist in the clinical assessment of lung donor suitability. In this invention, gene expression is calculated for a specific pair of up-regulated and down-regulated biomarkers or specific cytokine pairs, wherein the value of the gene ratio is indicative of the risk of primary graft failure posttransplantation. This gene ratio model is considered to be more predictive than monitoring expression levels of individual biomarkers alone. It has been demonstrated that the use of specific gene ratio pairs achieved greater than 90% diagnostic accuracy.
These biomarkers can be developed into novel diagnostic assay kits for lung transplant and can be used in conjunction with current selection criteria to improve screening of lung donor suitability in transplantation. It is anticipated that such a diagnostic assay would have large market demand as it would improve the efficiency donor lung utilization and improve transplant recipient outcomes.
send a message
less
|
|
|
|
ORGANIZATIONS
PROJECTS
There are no related projects for this profile.
RESOURCES
There are no related resources for this profile.
ATTACHMENTS
There are no downloads available for this profile.
OTHER INFORMATION
There is no other information available for this profile.
|
|
|
|
|
|
YOU MAY ALSO BE INTERESTED IN:
CATEGORIES
Application Area
Bioproducts and biomaterials,
Human health
Disciplinary Focus
Experimental biology and chemistry,
Informatics, theoretical biology and computer science,
Mathematics and engineering
Research Paradigm
Focused-scope projects,
Large-scale projects,
Technology development
Core Technology
Cells and tissues:
Biobanking,
Cell imaging
Nucleic acids:
Gene expression systems,
Genotyping,
Microarrays
Other molecules:
High-throughput small molecule screening
Proteins:
Protein-protein interaction assays
Sign-up to edit this profile
|
